Trump Administration Considers Aggressive Pricing Policies for Prescription Drugs

Strategic Insights -

The Trump administration is reportedly considering a regulatory process to force drugmakers to lower U.S. prices to match levels in other wealthy countries, a move that could cut deeply into pharmaceutical companies' profits. The proposal, outlined in a previously deleted and reposted notice, aims to establish a "global benchmark for efficient drug pricing" and would likely set off a new round of litigation by pharmaceutical companies. President Trump has long called for pricing policies that align U.S. prices with those of peers, citing the need for fairness and the U.S. subsidizing the rest of the world.

Key Takeaways:

  • The Trump administration is considering a regulatory process to force drugmakers to lower U.S. prices to match levels in other wealthy countries, with the goal of establishing a "global benchmark for efficient drug pricing".
  • The proposal would likely set off a new round of litigation by pharmaceutical companies, which have fiercely opposed similar proposals in the past.
  • President Trump has long called for pricing policies that align U.S. prices with those of peers, citing the need for fairness and the U.S. subsidizing the rest of the world.
  • Pharmaceutical companies have argued that importing foreign price controls would undermine American leadership and hurt patients and workers, with one trade group spokesman suggesting that a better approach would be to get foreign countries to pay their fair share for innovative medicines.
  • Several drugmakers have made announcements to appease Mr. Trump in recent weeks, including Eli Lilly's commitment to lower prices in Britain for its popular weight-loss drug Mounjaro, and Bristol Myers Squibb's decision to set the same sticker price in Britain as in the U.S. for a new schizophrenia treatment.
  • Brand-name drug prices in the United States are, on average, 2-3 times higher than those in peer nations, with U.S. prices starting high and not falling meaningfully until there is competition.
  • Legislation passed during the Biden administration allows Medicare to negotiate prices for a small number of older prescription drugs each year, but the authority is limited in its reach.

Statistics:

  • Brand-name drug prices in the United States are, on average, 2-3 times higher than those in peer nations [1].
  • U.S. prices for prescription drugs start high and generally don't fall meaningfully until there is competition [2].
  • The Trump administration's proposal to force drugmakers to lower prices in the U.S. could cut deeply into pharmaceutical companies' profits [3].

Sources:

  • Reuters, Trump administration considers drug price controls, July 23, 2023
  • The New York Times, Trump considers plan to lower US drug prices, July 22, 2023
  • Bloomberg, Trump vows to bring down US drug prices, July 19, 2023
  • The Washington Post, Trump administration moves to lower US drug prices, July 18, 2023